Accuray Incorporated Announces Underwriters' Exercise of Over-Allotment Option and Completion of Initial Public Offering
The public offering price of $18.00 per share resulted in net proceeds to the Company of approximately $171.3 million after deducting underwriting discounts and commissions and estimated offering expenses.
J.P. Morgan Securities Inc. and UBS Investment Bank served as joint book- running managers for the offering, with Piper Jaffray & Co. as lead manager and Jefferies & Company, Inc. as co-manager for the offering.
A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A final prospectus for the offering may be obtained from J.P. Morgan Securities Inc., Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, and UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, NY 10171.
Accuray designs, develops and sells the CyberKnife(R) System, an intelligent robotic radiosurgery system designed to treat solid tumors anywhere in the body.
NOTE: Accuray, the Accuray logo and CyberKnife are among trademarks or registered trademarks of Accuray Incorporated.
SOURCE Accuray Incorporated
Susan Lehman of Rockpoint Public Relations, +1-510-832-6006, or firstname.lastname@example.org; or Investors Robert McNamara, Sr., Vice President and CFO, +1-408-789-4264, or email@example.com